A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma (Mel62; 6PAC)

Clinical Trial ID NCT02385669

Rank	Title	Journal	Year	PubWeight™‹?›
1	Long-term outcomes of helper peptide vaccination for metastatic melanoma.	Ann Surg	2015	0.75